Deaths of despair—fatalities from drugs, alcohol, and suicide—declined by 16% in 2024 according to a report from Trust for America’s Health, signaling progress in the nation’s mental health crisis. The decline comes as regulatory agencies and pharmaceutical companies continue advancing treatment options, though obstacles persist in addressing behavioral health needs.
Policy and Drug Development Updates
Georgia’s Pathways to Coverage, a Medicaid expansion program that conditions eligibility on meeting monthly community engagement requirements, was tied to worsening mental health among income-eligible adults, according to an analysis of national surveillance data published in JAMA Network Open. The FDA rejected Cingulate’s dexmethylphenidate drug CTx-1301 for treating attention deficit-hyperactivity disorder due to manufacturing concerns. The agency also missed its deadline to ban electric shock therapy for managing self-injurious behavior in people with intellectual disabilities and autism, drawing criticism from disability advocates.
In emerging treatments, investigational sublingual dexmedetomidine (BXCL501) from BioXcel Therapeutics successfully reduced agitation across all severity levels in patients with schizophrenia or bipolar disorder. Otsuka’s investigational drug centanafadine, a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor, improved patient-reported executive function and emotional dysregulation in adults with ADHD according to phase III data analysis. Autobahn Therapeutics secured FDA fast track designation for elunetirom, an investigational daily pill for adjunctive treatment of depressive episodes in adults with bipolar I or II disorder.
Public Health Awareness
Public figures have increasingly opened up about mental health struggles. Tennis star Rafael Nadal discussed his battle with intense anxiety, while rapper Gucci Mane described his history with bipolar disorder and schizophrenia, noting episodes as “a total loss of control.”
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.medpagetoday.com/psychiatry/generalpsychiatry/121576